Published in Cancer Weekly, October 10th, 2000
He made his remarks at the Anticancer Biopharmaceuticals conference, held in San Francisco, California, during September 2000, and sponsored by Stephens, Inc.
Patient accrual to the company's ongoing Phase III trial of Genasense, Genta's lead antisense drug, in malignant melanoma remains on target for completion by mid-summer 2001. Warrell noted, "Long-term survival of patients in the original Phase I/II study now exceeds a median...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.